MedTrace Logo

Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma

NCT03682796 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-05-19

No results posted yet for this study

Summary

This is a Phase 1, multi-center, open-label study of TRPH-222 monotherapy in subjects with relapsed and/or refractory B-cell NHL. The study will be conducted in two Stages: Dose-Escalation, Dose-Expansion.

Conditions

  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin
  • Lymphoma, Mantle-Cell
  • Lymphoma, Marginal Zone
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, Follicular

Interventions

DRUG

TRPH-222

administered by IV, 21-day Cycle

Sponsors & Collaborators

  • Triphase Research and Development III Corp.

    lead INDUSTRY

Principal Investigators

  • Francisco J Hernandez- Ilizaliturri, MD · Roswell Park Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2021-11-17
Completion
2021-11-17
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03682796 on ClinicalTrials.gov